Wechselwirkungen · Anoro Ellipta (previously Anoro)
ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed · Abschnitt 4.5 · PDF-Seite 5
HOS-129127 · Präparat HOS-096681
Vilanterol is a substrate of cytochrome P450 3A4 (CYP3A4). Concomitant administration of strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin) may inhibit the metabolism of, and increase the systemic exposure to, vilanterol. Co-administration with ketoconazole (400 mg) in healthy volunteers increased mean vilanterol AUC(0-t) and Cmax, 65% and 22% respectively. The increase in vilanterol exposure was not associated with an increase in beta-adrenergic agonist related systemic effects on heart rate, blood potassium or QT interval (corrected using the Fridericia method). Care is advised when co-administering umeclidinium/vilanterol with ketoconazole and other known strong CYP3A4 inhibitors as there is potential for an increased systemic exposure to vilanterol, which could lead to an increase in the potential for adverse reactions. Verapamil, a moderate CYP3A4 inhibitor, did not significantly affect the pharmacokinetics of vilanterol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521) potassium (HOS-086929) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-31T09:00:00Z · SHA-256 55532081e38077e14b6448f7cc246b93ec49bd5a6fa1e010be00e4a9b8e25695 · Passage ed9621b0fd43fa1516b3c07ce8226bb493d2421d5335cf0596e0b5c257acda22 · Zeichen 514–1504 im Abschnitt